評估 AMG 510 口服每日一次用於帶有 KRAS p.G12C 突變的晚期／轉移性實體瘤的中國裔受試者的安全性、耐受性、藥物動力學及初步療效。
適應症：Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
收案條件
納入條件
- Male or female subjects greater than or equal to 18 years old
- Subject is of Chinese ancestry
- Pathologically documented, advanced/metastatic solid tumor with KRAS p.G12C mutation identified
排除條件
- Active brain metastases from non-brain tumors.
- Myocardial infarction within 6 months of study day 1.
- Gastrointestinal (GI) tract disease causing the inability to take oral medication
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。